Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
11:55am, Thursday, 17'th Oct 2024
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
08:35am, Thursday, 17'th Oct 2024
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ter
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
04:43pm, Wednesday, 16'th Oct 2024
Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
11:19am, Wednesday, 16'th Oct 2024
Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
10:23am, Wednesday, 16'th Oct 2024
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
08:25am, Wednesday, 16'th Oct 2024
Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE pr
How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71%
10:56am, Friday, 11'th Oct 2024
The mean of analysts' price targets for Wave Life Sciences (WVE) points to an 89.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
An Airline, Biotechs, and More See Huge Insider Buying
09:45am, Sunday, 06'th Oct 2024
24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
08:15am, Thursday, 03'rd Oct 2024
These two could become direct competitors relatively soon.
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
08:30am, Monday, 30'th Sep 2024
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
12:05pm, Thursday, 26'th Sep 2024
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences WVE, whose shares rose 9% the d
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
09:14pm, Wednesday, 25'th Sep 2024
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
08:55am, Wednesday, 25'th Sep 2024
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
04:01pm, Tuesday, 24'th Sep 2024
CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
